Follow the 大幸薬品株式会社 share price and the full management transaction log of the company, a publicly traded company based in Japan. Shares are quoted on the JP market, under the authority of EDINET (Japan FSA). Operating in the Health Care sector, 大幸薬品株式会社 has recorded 11 public disclosures. Market capitalisation: €12.7bn. The latest transaction was disclosed on 20 October 2023 (Holding update). Among the most active insiders: Nomura Securities Co.,Ltd.. All data is openly available.
11
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
13Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 4,028 of 28,548 companies
70.7
score / 100
Value
64
Quality
78
FCF yld4.0%
Earn yld7.3%
EV/EBITDA11.1x
ROE20%
Gross mgn54%
Net mgn14%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Daiichi Pharmaceutical Co., Ltd. es una empresa japonesa especializada en el sector de la salud y farmacéutico. Cotiza en la Bolsa de Tokio bajo el símbolo XTKS.